Scientists Have Submitted A New Drug To Treat HIV

Scientists Have Submitted A New Drug To Treat HIV.
Scientists are reporting antique but positive results from a redone drug that blocks HIV as it attempts to invade accommodating cells. The approach differs from most advised antiretroviral therapy, which tries to limit the virus only after it has gained going in to cells badhane. The medication, called VIR-576 for now, is still in the initial phases of development.

But researchers say that if it is successful, it might also circumvent the cure-all resistance that can undermine standard therapy, according to a report published Dec 22 2010 in Science Translational Medicine. The uncharted nearly equal is an attractive one for a number of reasons, said Dr Michael Horberg, headman of HIV/AIDS for Kaiser Permanente in Santa Clara, California vigrx top. "Theoretically it should have fewer subsidiary possessions and indeed had minimal adverse events in this study and there's indubitably less of a chance of mutation in developing resistance to medication," said Horberg, who was not active in the study.

Viruses replicate inside cells and scientists have dream of known that this is when they tend to mutate - potentially developing callow ways to resist drugs. "It's commonly accepted that it's harder for a virus to mutate highest cell walls".

The new drug focuses on HIV at this pre-invasion stage. "VIR-576 targets a separate of the virus that is different from that targeted by all other HIV-1 inhibitors," explained contemplation co-author Frank Kirchhoff, a professor at the Institute of Molecular Virology, University Hospital of Ulm in Ulm, Germany, who, along with several other researchers, holds a franchise on the unfamiliar medication. The quarry is the gp41 fusion peptide of HIV, the "sticky" end of the virus's outer membrane, which "shoots peer a 'harpoon'" into the body's cells, the authors said.